Results 171 to 180 of about 74,225 (263)

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

open access: yesBritish Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka   +3 more
wiley   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

open access: yesCancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang   +6 more
wiley   +1 more source

Adipocyte‐Derived Palmitic Acid Promotes Breast Cancer Malignancy via ZDHHC15‐Mediated S‐Palmitoylation of PPARγ

open access: yesCancer Science, EarlyView.
Adipocyte‐derived palmitic acid induces ZDHHC15‐mediated PPARγ S‐palmitoylation at Cys159, triggering its proteasomal degradation and promoting breast cancer malignancy with rosiglitazone resistance. Inhibition of PPARγ S‐palmitoylation by 2‐bromopalmitate suppresses breast cancer progression and synergistically enhances rosiglitazone efficacy ...
Geon Ho Moon   +6 more
wiley   +1 more source

PABPC1 in Cancer: From a Translational Housekeeper to a Stress‐Responsive Regulatory Hub

open access: yesCancer Science, EarlyView.
PABPC1 shifts from a translational housekeeper to a stress‐responsive oncogenic hub via phase separation, PTMs, and non‐coding RNA crosstalk, selectively driving oncogene translation and therapy resistance in cancer. ABSTRACT PABPC1, long recognized as a constitutive translational housekeeper, has emerged as a stress‐responsive translational ...
Cuiwei Zhang, Ye Zhu, Wenbo Long
wiley   +1 more source

Copper complexes in the triple-negative breast cancer landscape: advances and opportunities. [PDF]

open access: yesFront Mol Biosci
Lima PMAP   +4 more
europepmc   +1 more source

CDK4/6 Inhibitors and Curcumin Synergistically Suppress HER2− Breast Cancer via Lethal ROS and Inhibition of Metastasis

open access: yesCancer Science, EarlyView.
Schematic illustrating that CDK4/6 inhibitors combined with curcumin induce lethal ROS accumulation by disrupting redox balance, downregulating GPX4, and depleting glutathione, leading to DNA damage and lipid peroxidation. This oxidative stress triggers tumor cell death and suppresses EMT‐driven migration.
Chenyu Wang   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy